Results of the nationwide POET study published
The primary outcomes of Dutch POET study have been published in Arthritis & Rheumatology. POET is the world’s largest randomized trial on the effects of stopping TNF-inhibitor treatment in patients with rheumatoid arthritis. The study included over 800 patients from 47 hospitals across the Netherlands. Together with our primary technical development partner WAME, we developed a custom-made Electronic Case Record Form (eCRF) for this ambitious study. Using this system, physicians could enter the required clinical data and patients completed their patient-reported outcome measures (PROMs) in a single integrated online data collection system. The system was designed to strictly replicate the study protocol and allowed easy monitoring of the data collection and auditing of the content of the completed eCRFs.